FindTrial
Sign In

Phase III clinical trial for evaluation of prophylactic treatment with minocycline versus reactive treatment of dermatological toxicity secondary to cetuximab in patients with metastatic colorectal cancer

Phase III clinical trial for evaluation of prophylactic treatment with minocycline versus reactive treatment of dermatological toxicity secondary to cetuximab in patients with metastatic colorectal cancer

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-000877-29-PT
Enrollment
88
Registered
2011-05-05
Start date
2011-12-02
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 13.1 Level: PT Classification code 10037844 Term: Rash System Organ Class: 10040785 - Skin and subcutaneous tissue disorders

Interventions

Trade Name: Cipancin Pharmaceutical Form: Tablet CAS Number: 13614-98-7 Other descriptive name: MINOCYCLINE HYDROCHLORIDE

Sponsors

Grupo de Estudos Oncológicos
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 44 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 44

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Portugal

Contacts

Public ContactScientific&Business Vice-Director

KeyPoint, Consultoria Científica

imoital@grupokeypoint.pt+351214200480

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026